Affordable Access

Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.

Authors
  • Malamou-Mitsi, V
  • Gogas, H
  • Dafni, U
  • Bourli, A
  • Fillipidis, T
  • Sotiropoulou, M
  • Vlachodimitropoulos, D
  • Papadopoulos, S
  • Tzaida, O
  • Kafiri, G
  • Kyriakou, V
  • Markaki, S
  • Papaspyrou, I
  • Karagianni, E
  • Pavlakis, K
  • Toliou, T
  • Scopa, Cd
  • Papakostas, P
  • Bafaloukos, D
  • Christodoulou, C
  • And 1 more
Type
Published Article
Journal
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Publication Date
Oct 01, 2006
Volume
17
Issue
10
Pages
1504–1511
Identifiers
PMID: 16968874
Source
Medline
License
Unknown

Abstract

For both treatments, p53 positive expression was a significant negative prognostic factor for OS and DFS while Bcl-2 was not. No predictive ability of p53 status or Bcl-2 status for paclitaxel treatment was evident.

Report this publication

Statistics

Seen <100 times